April 24, 2020 / 2:46 PM / a month ago

BRIEF-Shanghai Henlius Biotech Receives Approval For Supplemental Drug Application Of Hlx01 Rituximab Injection

April 24 (Reuters) - Shanghai Henlius Biotech Inc:

* SHANGHAI HENLIUS BIOTECH INC- RECEIVED APPROVAL FOR SUPPLEMENTAL DRUG APPLICATION OF HLX01 (RITUXIMAB INJECTION) FROM NMPA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below